GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-44.5%
Return on equity
-42.8%
Return on assets
-53.3%
Return on invested capital
0.00x
Asset turnover
-$10.3M
Cash from operations
$0.65
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026